Zimmer Biomet (ZBH) Q1 2026 earnings review
Earnings Surge Despite Deliberate Revenue Deceleration
Zimmer Biomet successfully navigated the beginning of a messy transition year. Management previously warned that a massive U.S. sales force overhaul in 2026 would disrupt top-line growth and pressure margins. The top-line disruption materialized—organic revenue growth decelerated to 2.9% from 5.4% last quarter. However, the profitability shock did not. Adjusted operating margin expanded 110 basis points YoY to 27.3%, driving a massive 15.5% acceleration in Adjusted EPS. The company proved it can execute structural changes without destroying shareholder returns, leading to a confident raise in full-year EPS guidance.
🐂 Bull Case
Management had guided for a 50 bps operating margin decline in FY26. Instead, Q1 adjusted operating margin expanded to 27.3% (from 26.2% a year ago), proving the company can tightly manage costs during its commercial reorganization.
With the M&A pipeline paused, the company successfully executed $250 million in share repurchases in Q1 out of its newly authorized $1.5 billion program, providing a stable floor for EPS growth.
🐻 Bear Case
While total reported revenue grew 9.3%, stripping out the Paragon 28 acquisition and FX reveals sluggish 2.9% organic growth. The core Knees segment grew just 1.8% organically, trailing historical trends.
Management is transitioning 2,500 U.S. reps to a specialized model. With two-thirds of the transition still remaining over the next two years, execution risk remains high.
⚖️ Verdict: 🟢
Bullish. The market braced for a painful Q1 due to commercial disruptions. Delivering a 15% EPS beat, expanding margins, and raising full-year earnings guidance under these conditions demonstrates exceptional operational control.
Key Themes
Profitability Accelerating Through the Disruption
The most important takeaway from Q1 is that the U.S. sales force transition did not crush margins. Gross margin improved to 73.0% (from 71.5% in 25Q1), and operating margin jumped to 27.3% (from 26.2%). This allowed the company to drop a 15.5% Adjusted EPS increase to the bottom line on just 2.9% organic sales growth—a masterclass in operating leverage.
Technology & Data Segment Booming
The Technology & Data segment (formerly 'Other') was the clear organic growth leader, accelerating by 11.7% YoY. This validates the strategy to heavily push the ROSA Knee platform with the new OptimiZe upgrade, capturing capital equipment demand and driving the broader ecosystem.
The Paragon 28 Illusion in S.E.T.
The Sports Medicine, Extremities, Trauma (S.E.T.) segment reported a massive 19.5% revenue jump. However, this is almost entirely driven by the inorganic addition of Paragon 28. Strip out acquisitions and FX, and organic growth in S.E.T. was a highly decelerated 1.6%. Core operations here are lagging.
Knee Segment Losing Steam
Despite heavily touted launches like the Persona OsseoTi and Oxford partial cementless knees over the past year, global Knee organic growth decelerated to just 1.8%. Management previously acknowledged losing market share in U.S. Knees, and this print does not show a reversal of that trend.
Other KPIs
Stable. Down slightly from $278.5M in 25Q1, but remains highly robust. This liquidity directly funded the $250 million in share repurchases executed during the quarter, matching management's pivot from M&A to capital returns.
Stable. Grew 3.2% on an organic constant currency basis. The segment continues to benefit from the rollout of the Z1 Hip Stem and the newly cleared G7 Acetabular System, maintaining steady mid-single-digit expansion.
Guidance
Accelerating. Raised from prior guidance of $8.30 - $8.45. The midpoint ($8.475) implies a healthy 3.3% YoY growth from FY25's $8.20, impressive given the deliberate pause on M&A and structural sales disruptions.
Stable. Maintained from prior quarter. By maintaining this low bar while beating Q1 organically (2.9%), management has set themselves up for achievable beats in the back half of the year as long as the sales force transition holds together.
Stable. Maintained. Includes an estimated 100 bps tailwind from the Paragon 28 acquisition before it annualizes late in Q2, plus a minor 50 bps FX benefit.
Key Questions
S.E.T. Organic Weakness
With S.E.T. organic growth decelerating to 1.6%, what specific product lines (Trauma, Craniomaxillofacial, etc.) are dragging the core portfolio down while Paragon 28 covers the reported numbers?
Margin Durability
You delivered strong 110 bps operating margin expansion in Q1 despite previously guiding for a 50 bps decline for the full year. Was this timing of expenses, or a structural realization of cost-control faster than anticipated?
Knees Market Share
Global Knees grew just 1.8% organically. Are you seeing renewed pricing pressure, or is this primarily a temporary consequence of U.S. sales reps being distracted by territory realignments?